Last update Sept. 11, 2022
Apremilast is a non-steroidal drug, phosphodiesterase type 4 (PDE-4) inhibitor, used for the treatment of inflammatory conditions such as psoriasis and psoriatic arthritis. Oral administration in two daily doses. (Martindale)
Since the last update we have not found published data on its excretion in breastmilk.
Its low binding to plasma proteins and high pKa facilitates its excretion in breast milk, but its moderately high molecular weight and very large volume of distribution make it difficult.
The most common adverse effects are respiratory infections, diarrhoea, nausea, and headache. (Amgen 2020, EMA 2019)
Until more published data is known about this drug in relation to breastfeeding, known safer alternatives may be preferable (Puchner 2019, Rademaker 2018), especially during the neonatal period and in the event of prematurity.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM